Background The treatment landscape for chronic lymphocytic leukemia (CLL) continues to
undergo considerable evolution. Optimal selection of initial therapy from multiple effective …

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed
considerably with the introduction of very effective oral targeted therapies (such as Bruton …

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …

Background The combination of ibrutinib and venetoclax has been shown to improve
outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with …

Venetoclax-obinutuzumab (Ven-Obi) is a standard-of-care for patients with previously
untreated chronic lymphocytic leukemia (CLL). In the CLL14 study, patients with previously …

Background In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior
progression-free survival versus chlorambucil–obinutuzumab in patients with previously …

PURPOSE In GLOW, fixed-duration ibrutinib+ venetoclax showed superior progression-free
survival (PFS) versus chlorambucil+ obinutuzumab in older/comorbid patients with …

Complex karyotypes have been associated with inferior outcomes in chronic lymphocytic
leukemia (CLL) treated with chemoimmunotherapy (CIT), whereas their prognostic impact in …

The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response
and tolerability of the triple combination of obinutuzumab, ibrutinib, and venetoclax (GIVe …

Abstract Purpose: Mutations in BTK, PLCG2, and BCL2 have been reported in patients with
progressive disease (PD) on continuous single-agent BTK or BCL2 inhibitor treatment. We …